Anagen's safety-leaning combo: same minoxidil and supporting actives as Budget Growth Maxi, but with finasteride reduced to 0.005% — a 20× lower dose chosen to retain meaningful scalp DHT effect while minimizing systemic exposure.
Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.
| Active | Grade | Why it's in this formula |
|---|---|---|
| Finasteride0.005%→Sub-systemic DHT suppression | B | Ultra-low-dose topical finasteride — 20× lower than the 0.1% used in Growth Maxi. The Caserini pharmacokinetic work on topical finasteride 0.25% shows dose-dependent systemic absorption; at 0.005%, circulating finasteride should be substantially lower while preserving local scalp activity. Trades some efficacy ceiling for a far tighter side-effect envelope. |
| Minoxidil5%→Follicular activator | A | Full-dose topical 5% minoxidil — same as the other Anagen combos. Carries the primary efficacy load in this formulation given the reduced finasteride dose. |
| Liothyronine (T3)6.5 ng/mL→Anagen induction | C | Same microdose T3 used across Anagen's topicals. |
| Levocetirizine0.5%→Anti-inflammatory / anti-PGD2 | C | PGD2 inhibition adjunct with the Zaky 2021 supporting evidence. |
The 0.005% topical finasteride concentration has not been directly studied in an RCT — Anagen's case rests on extrapolation from the Caserini pharmacokinetic work at 0.25% and the established efficacy ceiling of full-strength fin + min combinations. Here are the most directly relevant studies.
Pharmacokinetic study in healthy male volunteers
—
Multi-dose
Topical finasteride 0.25% showed measurably lower plasma finasteride levels than oral 1 mg (Cmax 0.46 ± 0.28 ng/mL, AUC 6.64 ± 7.50 ng/mL·h after multiple doses). Establishes the basic principle that topical fin reduces systemic exposure relative to oral.
Pharmacokinetic/pharmacodynamic study
—
—
Serum DHT reduction was -24% to -26% with 100–200 µL of 0.25% topical fin and -44% to -48% with 300–400 µL — demonstrating dose-dependent systemic effect. At 0.005% (50× lower concentration), serum DHT impact should be substantially smaller.
Meta-analysis of 7 RCTs
396
—
Topical fin + min beats min alone on hair density, diameter, and global photographic assessment. The meta-analysis used 0.1% finasteride concentrations; whether the magnitude of benefit holds at 0.005% is the open question this formulation extrapolates into.
Not too much, not too little. A balanced formula for steady hair growth, with a low dose of finasteride.
Long-form analysis and primary-source breakdowns that go beyond the summary above.
How does Mr. Middleground compare to its closest Anagen siblings?
Anagen's safety-leaning combo: same minoxidil and supporting actives as Budget Growth Maxi, but with finasteride reduced to 0.005% — a 20× lower dose chosen to retain meaningful scalp DHT effect while minimizing systemic exposure.
Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.
| Active | Grade | Why it's in this formula |
|---|---|---|
| Finasteride0.005%→Sub-systemic DHT suppression | B | Ultra-low-dose topical finasteride — 20× lower than the 0.1% used in Growth Maxi. The Caserini pharmacokinetic work on topical finasteride 0.25% shows dose-dependent systemic absorption; at 0.005%, circulating finasteride should be substantially lower while preserving local scalp activity. Trades some efficacy ceiling for a far tighter side-effect envelope. |
| Minoxidil5%→Follicular activator | A | Full-dose topical 5% minoxidil — same as the other Anagen combos. Carries the primary efficacy load in this formulation given the reduced finasteride dose. |
| Liothyronine (T3)6.5 ng/mL→Anagen induction | C | Same microdose T3 used across Anagen's topicals. |
| Levocetirizine0.5%→Anti-inflammatory / anti-PGD2 | C | PGD2 inhibition adjunct with the Zaky 2021 supporting evidence. |
The 0.005% topical finasteride concentration has not been directly studied in an RCT — Anagen's case rests on extrapolation from the Caserini pharmacokinetic work at 0.25% and the established efficacy ceiling of full-strength fin + min combinations. Here are the most directly relevant studies.
Pharmacokinetic study in healthy male volunteers
—
Multi-dose
Topical finasteride 0.25% showed measurably lower plasma finasteride levels than oral 1 mg (Cmax 0.46 ± 0.28 ng/mL, AUC 6.64 ± 7.50 ng/mL·h after multiple doses). Establishes the basic principle that topical fin reduces systemic exposure relative to oral.
Pharmacokinetic/pharmacodynamic study
—
—
Serum DHT reduction was -24% to -26% with 100–200 µL of 0.25% topical fin and -44% to -48% with 300–400 µL — demonstrating dose-dependent systemic effect. At 0.005% (50× lower concentration), serum DHT impact should be substantially smaller.
Meta-analysis of 7 RCTs
396
—
Topical fin + min beats min alone on hair density, diameter, and global photographic assessment. The meta-analysis used 0.1% finasteride concentrations; whether the magnitude of benefit holds at 0.005% is the open question this formulation extrapolates into.
Not too much, not too little. A balanced formula for steady hair growth, with a low dose of finasteride.
Long-form analysis and primary-source breakdowns that go beyond the summary above.
How does Mr. Middleground compare to its closest Anagen siblings?
